Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

31

Revenue 2017

NovoRapid

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. NovoRapid was produced by Novo Nordisk.

Novo Nordisk growth takes a hit with China deal

Novo Nordisk growth takes a hit with China deal

Ryzodeg contains a combination of long acting insulin degludec – which Novo markets as Tresiba – and rapid-acting insulin aspart, while Novo sells as NovoRapid. ... The assumption from Novo’s announcement is that Tresibo and NovoRapid, as well as

Ypsomed’s touch screen insulin pump for Novo Nordisk approved by EMA

Ypsomed’s touch screen insulin pump for Novo Nordisk approved by EMA The mylife YpsoPump is fitted with a touch screen, reducing the need for training, and is fully compatible with Novo Nordisk's prefilled pump cartridge, NovoRapid PumpCart, which negates the need ... NovoRapid was awarded a European license in 1999 and

Prescribing costs jump in England

Prescribing costs jump in England After Seretide, another respiratory drug from AstraZeneca - Symbicort - saw the second highest spend with £89m, while Novo Nordisk's insulin NovoRapid came in third with the NHS spending £75m on the

Hanover wins Novo Nordisk public affairs and policy account

Hanover wins Novo Nordisk public affairs and policy account Novo has built its business on a range of diabetes, led by currently the insulins Levemir, NovoRapid and Tresiba and the GLP-1 agonist Victoza (liraglutide).

Novo Nordisk will build $100m facility in Denmark

Novo Nordisk will build $100m facility in Denmark These include Tresiba-based combination therapy IDegLira, which incorporates insulin degludec plus liraglutide (the API in GLP-1 agonist Victoza), a revamped version of fast-acting insulin product NovoLog/NovoRapid (insulin

1 2 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Visformatics (VISFO)

A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...